1994
DOI: 10.1172/jci117032
|View full text |Cite
|
Sign up to set email alerts
|

Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep.

Abstract: Invest. 1994. 93:776-787.)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

16
119
0
1

Year Published

1995
1995
2007
2007

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 206 publications
(136 citation statements)
references
References 55 publications
16
119
0
1
Order By: Relevance
“…Thus, while described above, BIO-1211, HMR 1031, IVL745, TR14035, or GW559090X α4β1 antagonists have negligible benefit in human asthma clinical trials, these compounds have had significant effects in sheep [118,121,126], mouse [121,127], rat [118,123,128], or guinea pig [123] models of asthma. The HP1/2, PS2/3, PS/2, TA-2, or Max-68P anti-α4 blocking antibodies, CS-1 peptide ligand anti-α4β1 mimic, or α4β1 small molecule inhibitors reduce either numbers of eosinophils in the airway or ameliorate inflammatory histopathology or airway allergic responses in the guinea pig [129][130][131][132][133], sheep [134][135][136][137], mouse [138][139][140], rat [141,142], or rabbit [143]. A complication of such studies is the failure to differentiate between effects resulting from eosinophils, roles of integrins of eosinophils, or roles of other cell types [144][145][146][147].…”
Section: Targeting Eosinophil Integrins In Vivomentioning
confidence: 99%
“…Thus, while described above, BIO-1211, HMR 1031, IVL745, TR14035, or GW559090X α4β1 antagonists have negligible benefit in human asthma clinical trials, these compounds have had significant effects in sheep [118,121,126], mouse [121,127], rat [118,123,128], or guinea pig [123] models of asthma. The HP1/2, PS2/3, PS/2, TA-2, or Max-68P anti-α4 blocking antibodies, CS-1 peptide ligand anti-α4β1 mimic, or α4β1 small molecule inhibitors reduce either numbers of eosinophils in the airway or ameliorate inflammatory histopathology or airway allergic responses in the guinea pig [129][130][131][132][133], sheep [134][135][136][137], mouse [138][139][140], rat [141,142], or rabbit [143]. A complication of such studies is the failure to differentiate between effects resulting from eosinophils, roles of integrins of eosinophils, or roles of other cell types [144][145][146][147].…”
Section: Targeting Eosinophil Integrins In Vivomentioning
confidence: 99%
“…However, results of antibody studies vary with the animal model used or the route of antibody administration, and off-target effects can not be excluded [10][11][12][13][14]. To avoid the ambiguity of antibody-based studies and to carry out long-term observations, mouse models with genetically modified integrin genes have been generated [15][16][17].…”
Section: Introductionmentioning
confidence: 99%
“…Significant differences compared with control isotype (challenged with OA) are indicated: *, P < 0.05; t, P < 0.005; *, P < 0.001. mark of asthma (10). Although BHR is reported to correlate with the number of eosinophils in lungs staining positively with a monoclonal antibody that recognizes secreted eosinophil cationic protein (10)(11)(12)(13), there is no formal evidence for a causal relationship between eosinophil recruitment per se and BHR in humans (14,15), sheep (16), and guinea pigs (4). Few studies have addressed the correlation between eosinophil recruitment to the airways and BHR in mice, possibly because the evaluation of their pulmonary functions was considered difficult or unreliable.…”
mentioning
confidence: 99%